Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled dose-ranging study of INV-202 in diabetic kidney disease
MOH_2023-01-29_012132Phase 2Completed
- Sponsor
- Inversago
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of monlunabant in diabetic glomerulosclerosis (3 arms), sponsored by Inversago. Primary endpoint: Primary efficacy endpoint. Started Oct 2022; status: completed.
02
Drugs
monlunabant
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on MOH_2023-01-29_012132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-29_012132.